0 Members and 1 Guest are viewing this topic.
New York-based Pfizer, which is evaluating at least four experimental vaccines with Germany’s BioNTech, reported positive preliminary data from one of its candidates earlier this week. Beatty said Pfizer “will not rely on taxpayer dollars in the development or manufacture of the vaccine candidate,†and thus is shouldering all of the risk in bringing a shot to market.In the Pfizer deal, the U.S. agreed to secure 100 million doses of its vaccine candidate. The payment depends on approval from the U.S. Food and Drug Administration and the ability to successfully manufacture it, Pfizer’s Beatty said. The time line for supply is not yet known.The U.S. can acquire as many as 500 million additional doses, though Pfizer “will need to separately negotiate the terms for the remaining doses if the U.S. orders more,†according to Beatty.
Author
Topic: Pfizer Vaccine Deal at $20 a Dose Sets Ceiling for Rivals (Read 363 times)
